BCTXW   $0.31  3.33% Market Closed

BriaCell Therapeutics Corp
Last Events:

2023-08-09 Trend pattern changed from канал to сужающийся канал.

2023-08-09 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it falls. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish recovery to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Trend pattern changed from сужающийся канал to канал.

2023-08-04 Trend pattern changed from нисходящий клин to сужающийся канал.

2023-08-04 Signal in RSI changed from bullish to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-03 Trend pattern changed from сужающийся канал to нисходящий клин.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd None None None
stoch None None None
ma20 Buy Sell Sell
ma50 None None None
ma100 Sell Sell Sell
Candlestick PatternOct. 1, 2024 Bearish Belt Hold - is a candlestick that has a long black body and small shadows. It opens on the high of the day. It occurs in a uptrend. Considered to be a bearish reversal pattern.
ISIN CA10778Y1126
ceo Dr. William V. Williams M.D.
Website https://briacell.com
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.